[go: up one dir, main page]

LT3463365T - Priešgrybelinė farmacinė kompozicija - Google Patents

Priešgrybelinė farmacinė kompozicija

Info

Publication number
LT3463365T
LT3463365T LTEPPCT/GB2017/051494T LTGB2017051494T LT3463365T LT 3463365 T LT3463365 T LT 3463365T LT GB2017051494 T LTGB2017051494 T LT GB2017051494T LT 3463365 T LT3463365 T LT 3463365T
Authority
LT
Lithuania
Prior art keywords
pharmaceutical formulation
antifungal pharmaceutical
antifungal
formulation
pharmaceutical
Prior art date
Application number
LTEPPCT/GB2017/051494T
Other languages
English (en)
Inventor
Derek Law
Graham Edward Morris SIBLEY
Original Assignee
F2G Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F2G Limited filed Critical F2G Limited
Publication of LT3463365T publication Critical patent/LT3463365T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/GB2017/051494T 2016-05-25 2017-05-25 Priešgrybelinė farmacinė kompozicija LT3463365T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609222.3A GB201609222D0 (en) 2016-05-25 2016-05-25 Pharmaceutical formulation
PCT/GB2017/051494 WO2017203270A1 (en) 2016-05-25 2017-05-25 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
LT3463365T true LT3463365T (lt) 2021-11-10

Family

ID=56369959

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/GB2017/051494T LT3463365T (lt) 2016-05-25 2017-05-25 Priešgrybelinė farmacinė kompozicija

Country Status (25)

Country Link
US (2) US10973821B2 (lt)
EP (1) EP3463365B1 (lt)
JP (1) JP7141108B2 (lt)
KR (1) KR102464150B1 (lt)
CN (1) CN109982704B (lt)
AU (1) AU2017270942B2 (lt)
CA (1) CA3024771A1 (lt)
CY (1) CY1124733T1 (lt)
DK (1) DK3463365T3 (lt)
ES (1) ES2888951T3 (lt)
GB (1) GB201609222D0 (lt)
HR (1) HRP20211795T1 (lt)
HU (1) HUE056129T2 (lt)
IL (1) IL263167B (lt)
LT (1) LT3463365T (lt)
MA (1) MA45126A (lt)
MX (1) MX382199B (lt)
MY (1) MY197663A (lt)
PL (1) PL3463365T3 (lt)
PT (1) PT3463365T (lt)
RU (1) RU2760681C2 (lt)
SG (1) SG11201810323RA (lt)
SI (1) SI3463365T1 (lt)
WO (1) WO2017203270A1 (lt)
ZA (1) ZA201807851B (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
WO2021222045A1 (en) * 2020-04-26 2021-11-04 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
CN113429396A (zh) * 2021-06-08 2021-09-24 深圳市祥根生物医药有限公司 一种五元杂芳环衍生物及其制备方法和用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051723A (lt) 1962-04-27
US3202654A (en) 1962-04-27 1965-08-24 Bristol Myers Co 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof
US3252970A (en) 1963-02-27 1966-05-24 Ciba Geigy Corp Aromatization
BE631632A (lt) 1963-04-26
US3268558A (en) 1964-11-05 1966-08-23 Ortho Pharma Corp 1-r-2, 4-dinitropyrroles
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
GB1208014A (en) 1967-03-23 1970-10-07 Glaxo Lab Ltd Cephalosporins
US3573294A (en) 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
BE790747A (fr) 1971-10-30 1973-02-15 Whitefin Holding Sa Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
BE848465A (fr) 1976-11-18 1977-03-16 Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent
US4316900A (en) 1977-10-05 1982-02-23 Ciba-Geigy Corporation Piperazinopyrrolobenzodiazepines
JPS57142966A (en) 1981-02-27 1982-09-03 Sagami Chem Res Center (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative
JPS57144255A (en) 1981-03-03 1982-09-06 Sagami Chem Res Center Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative
US4761424A (en) 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
FR2601368B1 (fr) 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
BR9508298A (pt) 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
US5750540A (en) 1995-04-28 1998-05-12 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
DE69517160T2 (de) 1995-06-06 2000-11-16 Agfa-Gevaert N.V., Mortsel Photographische Materialien
JPH09249669A (ja) 1996-03-13 1997-09-22 Ono Pharmaceut Co Ltd 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤
PT986403E (pt) 1997-06-13 2004-04-30 Cydex Inc Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
BR9815920A (pt) 1998-06-03 2001-02-20 Gpi Nil Holding Inc Compostos aza-heterocìclicos usados para tratar distúrbios neurológicos e queda de cabelo
ATE404178T1 (de) 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6583136B1 (en) 1999-05-04 2003-06-24 Janssen Pharmacuetica N.V. Antifungal ethers
AU6438800A (en) 1999-07-30 2001-02-19 Norbert Heske Cannula system for introducing endoscopic tools in a human or animal body
TR200201617T2 (tr) 1999-12-23 2002-10-21 Pfizer Products Inc. Kuvvetlendirilmiş ilaç konsantrasyonları sağlayan farmasötik kompozisyonlar
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US7078209B2 (en) 2001-06-06 2006-07-18 Vertex Pharmaceuticals Incorporated CAK inhibitors and uses thereof
JP4128138B2 (ja) 2001-06-20 2008-07-30 第一三共株式会社 ジアミン誘導体
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1476163A4 (en) 2002-02-23 2009-05-27 Bristol Myers Squibb Co METHOD FOR TREATING HIV INFECTION BY PREVENTING INTERACTION OF CD4 AND GP120
JP2006500387A (ja) 2002-08-15 2006-01-05 雲清 劉 固形ナノ医薬およびその調製方法
US20050032871A1 (en) 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
TW200505915A (en) 2003-03-13 2005-02-16 Synta Pharmaceuticals Corp Fused pyrrole compounds
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
KR20060123184A (ko) 2003-10-24 2006-12-01 쉐링 악티엔게젤샤프트 인돌리논 유도체, 및 암과 같은 질환 상태의 치료에있어서의 이들의 용도
ATE409462T1 (de) 2004-05-28 2008-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
US20060058286A1 (en) 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
WO2006082518A1 (en) 2005-02-03 2006-08-10 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
US7842810B2 (en) 2005-03-31 2010-11-30 Janssen Pharmaceutica, Nv Bicyclic pyrazole compounds as antibacterial agents
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
JP5172661B2 (ja) 2005-05-18 2013-03-27 エフ2ジー リミテッド 抗真菌剤
CA2613458A1 (en) 2005-07-12 2007-01-18 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
AU2007226984B2 (en) 2006-03-20 2013-02-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20080118500A1 (en) 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
CN101622302B (zh) 2007-01-26 2013-01-23 Isp投资公司 生产喷雾干燥产品的制剂工艺方法
CN101260086B (zh) 2007-03-06 2011-08-10 中国科学院上海药物研究所 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途
GB0710121D0 (en) 2007-05-25 2007-07-04 F2G Ltd Antifungal agents
US20100215747A1 (en) 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
NZ589010A (en) 2008-04-24 2012-11-30 F2G Ltd Pyrrole antifungal agents
GB0809773D0 (en) 2008-05-29 2008-07-09 F2G Ltd Antifungal combination therapy
US20100093872A1 (en) 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
CA2760305A1 (en) 2009-04-28 2010-11-04 Boehringer Ingelheim International Gmbh Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
KR101807338B1 (ko) 2010-06-14 2018-01-10 다우 글로벌 테크놀로지스 엘엘씨 아세테이트 및 석신에이트 치환이 향상된 하이드록시프로필 메틸 셀룰로즈 아세테이트 석신에이트
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US20130288956A1 (en) 2010-11-05 2013-10-31 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
US20120308662A1 (en) 2011-06-01 2012-12-06 Nitto Denko Corporation Particulate preparation and method for producing the same
CA2852716C (en) 2011-11-29 2015-11-17 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
KR20140146181A (ko) 2012-04-11 2014-12-24 다우 글로벌 테크놀로지스 엘엘씨 특정 치환체 분포를 갖는 에스테르화된 셀룰로즈 에테르
JP6224711B2 (ja) 2012-08-24 2017-11-01 ダウ グローバル テクノロジーズ エルエルシー 部分架橋結合型エステル化セルロースエーテル
CN104981483B (zh) 2012-08-24 2017-10-24 陶氏环球技术有限责任公司 新的羟烷基甲基醋酸琥珀酸纤维素
UA116004C2 (uk) 2013-01-22 2018-01-25 Ф. Хоффманн-Ля Рош Аг Фармацевтична композиція з покращеною біодоступністю
WO2015007759A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
JP6272475B2 (ja) 2013-07-19 2018-01-31 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物
JP6505705B2 (ja) 2013-12-05 2019-04-24 アルライズ バイオシステムズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 経口投与用製剤の製造方法
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
WO2016079536A1 (en) 2014-11-21 2016-05-26 F2G Limited Antifungal agents
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation

Also Published As

Publication number Publication date
MX2018014232A (es) 2019-03-28
SI3463365T1 (sl) 2022-01-31
EP3463365B1 (en) 2021-08-25
GB201609222D0 (en) 2016-07-06
SG11201810323RA (en) 2018-12-28
PT3463365T (pt) 2021-09-28
CN109982704A (zh) 2019-07-05
JP7141108B2 (ja) 2022-09-22
IL263167B (en) 2022-07-01
RU2018142381A3 (lt) 2020-09-30
JP2019516765A (ja) 2019-06-20
MY197663A (en) 2023-06-30
HUE056129T2 (hu) 2022-01-28
IL263167A (en) 2018-12-31
AU2017270942B2 (en) 2022-07-21
PL3463365T3 (pl) 2022-01-10
EP3463365A1 (en) 2019-04-10
MX382199B (es) 2025-03-13
NZ748394A (en) 2024-11-29
HRP20211795T1 (hr) 2022-03-18
AU2017270942A1 (en) 2018-12-06
US20190328737A1 (en) 2019-10-31
ES2888951T3 (es) 2022-01-10
US10973821B2 (en) 2021-04-13
DK3463365T3 (da) 2021-09-20
CY1124733T1 (el) 2022-07-22
CA3024771A1 (en) 2017-11-30
RU2018142381A (ru) 2020-06-25
BR112018074162A2 (pt) 2019-03-06
ZA201807851B (en) 2022-04-28
KR102464150B1 (ko) 2022-11-07
US20210186967A1 (en) 2021-06-24
CN109982704B (zh) 2023-10-24
RU2760681C2 (ru) 2021-11-29
KR20190013865A (ko) 2019-02-11
WO2017203270A1 (en) 2017-11-30
MA45126A (fr) 2021-04-14

Similar Documents

Publication Publication Date Title
IL271226A (en) medical preparation
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
IL266537A (en) pharmaceutical preparation
IL253570B (en) Pharmacy composition
IL253177A0 (en) Pharmacy preparation
IL263040A (en) Pharmaceutical composition comprising eteplirsen
ZA201807851B (en) Pharmaceutical formulation
GB201615917D0 (en) Pharmaceutical composition
GB201608356D0 (en) Formulation
GB201506755D0 (en) Novel pharmaceutical formulation
SI3601277T1 (sl) Farmacevtska formulacija
IL275144A (en) Pharmacy preparation
GB201615914D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
GB201511246D0 (en) Pharmaceutical formulation
GB201707615D0 (en) Formulation
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
GB201616088D0 (en) Pharmaceutical composition
GB201609968D0 (en) Topical pharmaceutical formulation
GB201719873D0 (en) Pharmaceutical formulation
PL3559185T3 (pl) Preparat nabłyszczający
GB201604545D0 (en) Novel pharmaceutical formulation
GB201620515D0 (en) Pharmaceutical composition
GB201620516D0 (en) Pharmaceutical composition
GB201620513D0 (en) Pharmaceutical composition